Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
157results about How to "Poor prognosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Beta-catenin is a strong and independent prognostic factor for cancer
InactiveUS20030064384A1Poor prognosisStrong and independent prognostic factor in cancerGenetic material ingredientsMicrobiological testing/measurementTransactivationFactor ii
Cyclin D1 is one of the targets of beta-catenin in breast cancer cells. Transactivation of beta-catenin correlated significantly with cyclin D1 expression both in eight breast cell lines in vitro and in 123 patient samples. More importantly, high beta-catenin activity significantly correlated with poor prognosis of the patients and is a strong and independent prognostic factor in breast cancer (p<0.001). Moreover, by multivariate analyses, the inventors found that activated beta-catenin is a strong prognostic factor which provided additional and independent predictive information on patients survival rate even when other prognostic factors, including lymph node metastasis, tumor size, estrogen receptor and progesterone receptor status, were taken into account (p<0.001). This invention demonstrates that beta-catenin is involved in breast cancer formation and / or progression and may serve as a target for breast cancer therapy.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Prosthodontic and orthodontic apparatus and methods
ActiveUS8807999B2Reduce removalPromote resultsMedical simulationImpression capsDental patientsProsthodontics
System and method for developing a treatment plan for achieving a treatment goal including creating a virtual model of a dental patient's dentition; transforming the virtual model of the dentition using virtual prosthodontics to facilitate achievement of the treatment goal; transforming the virtual model of the dentition using virtual orthodontics to facilitate achievement of the treatment goal; iterating on the transforming steps until substantially achieving the treatment goal; and generating an orthodontic treatment plan and a prosthodontic treatment plan based upon the substantially achieved treatment goal
Owner:ALIGN TECH
Cyr61 as a Biomarker for Diagnosis and Prognosis of Cancers of Epithelial Origin
ActiveUS20080286811A1Easy diagnosisRaise the possibilityMicrobiological testing/measurementBiological material analysisBacteriuriaOncology
Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.
Owner:CHILDRENS MEDICAL CENT CORP
Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
InactiveUS20120171201A1Reduce resistanceTherapeutic utilityAntibody ingredientsImmunoglobulinsPolymeric prodrugMedicine
The present invention relates to methods of treating a HER2 positive cancer in mammals. The present invention includes administering a HER2 antagonist in combination with a polymeric prodrug of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof.
Owner:BELROSE PHARMA
Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
InactiveUS20040022873A1No toxicityWithout fear of compromisingBiocideTripeptide ingredientsWhole bodyPoisonous effects
The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and / or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as Bacillus anthracis and smallpox virus, and alternatively, upon exposure to radiation, during testing, and vaccination, as treatment prior to treatment with antibiotic or antiviral therapy to ameliorate the toxic effects of infection and exposure with these organisms.
Owner:YOUR ENERGY SYST
Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component
InactiveUS20080274118A1Improve expression levelPoor prognosisNervous disorderAntipyreticAutoimmune responsesSignal on
Methods for identifying subjects having an inflammatory disease and / or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
Owner:XOMA TECH LTD
Cancer Markers
InactiveUS20080188405A1Prognosis is dramatically affected by Numb statusImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementImmunologyCancer marker
Owner:IFOM FOND INST FIRC DI ONCOLOGIA MOLECOLARE
RNA expression profile predicting response to tamoxifen in breast cancer patients
InactiveUS20060246470A1Improve understandingAccurate identificationMicrobiological testing/measurementDUSP6Rna expression
The present invention regards predicting a response to a therapy using RNA expression profiling. In particular, a resistance to a chemotherapy, such as tamoxifen, is predicted by comparing expressed genes in a patient on the therapy to a patient sensitive to the chemotherapy. In further embodiments, there is an RNA expression profile indicative of tamoxifen resistance in an individual. In additional embodiments, the RNA expression profile comprises DUSP6 EBP50, and / or RhoGDIa.
Owner:BAYLOR COLLEGE OF MEDICINE
Anticancer compounds and methods
InactiveUS20060078535A1Inhibit tumor invasionInhibit growthPeptide/protein ingredientsNanomedicineLymphatic SpreadHuman tumor
The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.
Owner:RGT UNIV OF MICHIGAN
Antagonists of HMG1 for treating inflammatory conditions
InactiveUS7060504B2Poor prognosisToxic reactionAntibacterial agentsPeptide/protein ingredientsDrugARDs - Acute respiratory distress syndrome
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Methods and compositions for the treatment of cancer
ActiveUS20140186295A1Inhibited melanoma growthEnhancing tumor immunityBiocidePeptide/protein ingredientsMelanomaAgonist
Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9 expression in the subject (e.g. administration of TH9 cells that express IL-9, or administration of an inhibitor of ROR).
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Interleukin-10 Polypeptide Conjugates and Their Uses
InactiveUS20150038678A1Long half-lifeEnhance tumor killing activityDepsipeptidesPeptide preparation methodsInterleukin 10Cytokine synthesis
This invention relates to interleukin-10 (IL-10) polypeptide conjugates comprising at least one non-naturally-encoded amino acid.
Owner:AMBRX
Inhibition of microtubule protrusion in cancer cells
ActiveUS20090137473A1Reduce microtentaclesImprove the level ofBiocidePeptide/protein ingredientsCancer cellCancer stem cell
The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the protrusions interferes with attachment of the cell to a vessel wall, and in further aspects the cell is killed by forcing it to enter capillaries and be destroyed, for example by shearing. Inhibition by a variety of agents and methods is contemplated.
Owner:UNIV OF MARYLAND
Compositions and methods for prognosis and therapy of liver cancer
InactiveUS20050089895A1Poor prognosisHigh probabilitySugar derivativesMicrobiological testing/measurementLiver cancerMEG3
This invention provides a composition comprising the following polynucleotide probes: IL7R (AA485865), NDRG1 (AA486403), EST1 (H50345), TRPC1 (AA017132), GFRA1 (AA512935), EST2 (AA454543), CLDN10 (R54559), DNALI1 (R93087), RBP5 (AA453198), EST3 (AA621761), EST4 (N63706), PCOLCE (AA670200), TDO2 (T72398), EST5 (T47454), HIST1H2BD (N33927), PXMP2 (N70714), ACAS2 (AA455146), ANAPC7 (T68445), EST6 (AA576580), RBP5 (N92148), ANXA1 (H63077), CKB (AA894557), ITGBL1 (N52533), KPNA2 (AA676460), EST7 (W90740) and MEG3 (W85841). This invention further provides methods for determining the likelihood of recurrence of hepatocellular carcinoma (HCC) in a subject afflicted with HCC, for determining the likelihood of death of a subject afflicted with HCC or for determining whether to administer adjuvant therapy.
Owner:THE UNIVERSITY OF HONG KONG
Classification of Breast Cancer Patients Using a Combination of Clinical Criteria and Informative Genesets
InactiveUS20080187909A1Improved prognosisPoor prognosisNucleotide librariesMicrobiological testing/measurementComputerized systemOncology
The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.
Owner:NETHERLANDS CANCER INST THE +1
14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types
ActiveUS7316907B2Inhibition is effectiveLow survival rateGenetic material ingredientsMicrobiological testing/measurementDiseaseApoptosis
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Integrated Ultrasound, OCT, PA and/or Florescence Imaging Endoscope for Diagnosing Cancers in Gastrointestinal, Respiratory, and Urogenital Tracts
ActiveUS20160242737A1Poor prognosisImprove diagnostic accuracyUltrasonic/sonic/infrasonic diagnosticsGastroscopesTissue biopsyFluorescence
A multimodality imaging system including ultrasound, optical coherence tomography (OCT), photoacoustic (PA) imaging, florescence imaging and endoscopic catheter for imaging inside the gastrointestinal tract with real-time automatic image co-registration capability, including: an ultrasound subsystem for imaging; an optical coherence tomography (OCT) subsystem for imaging, a PA microscopy or tomography subsystem for imaging and a florescence imaging subsystem for imaging. An invasive interventional imaging device is included with an instrumentality to take a tissue biopsy from a location visible on the ultrasound subsystem for imaging, on the optical coherence tomography (OCT) subsystem for imaging, photoacoustic (PA) subsystem for imaging and florescence subsystem for imaging. The instrumentality takes a tissue biopsy from a visible location simultaneously with the visualization of the tissue about to be biopsied so that the tissue biopsy location is visualized before, during and after the biopsy.
Owner:UNIV OF SOUTHERN CALIFORNIA +1
Identifying circulating tumor cells (CTCS) using cd146 in breast cancer patients
InactiveUS20120178645A1Increased riskPoor prognosisMicrobiological testing/measurementLibrary screeningCirculating cancer cellBiology
The present invention relates to a method for diagnosing cancer in a subject said method comprising the steps of providing a biological sample from a subject, and determining the expression of the MCAM gene in a circulating tumor cell (CTC) in said biological sample.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Chronic Traumatic Encephalopathy in Blast-Exposed Individuals
InactiveUS20150119273A1Delay progressIncreased riskLibrary screeningDisease diagnosisCvd riskBrains tissue
The invention is based on the surprising discovery that as few as one episode of blast exposure increases the risk of CTE. Blast exposure is associated with chronic traumatic encephalopathy, impaired neuronal function, and persistent cognitive deficits in blast-exposed military veterans and experimental animals. Early diagnosis and assessment of risk permits physicians to prescribe treatment to reduce or slow progression of impairment before the onset of overt symptoms that become apparent decades after an initial insult or trauma to brain tissue. The invention provides methods and compositions for diagnosis and prognosis of individuals at risk of long term complications related to blast injury or concussive injury.
Owner:TRUSTEES OF BOSTON UNIV +1
Multigene assay to predict outcome in an individual with glioblastoma
InactiveUS20100167939A1Poor prognosisDecrease likelihoodNucleotide librariesMicrobiological testing/measurementHousekeeping geneHousekeeping
The present invention concerns prognosis for glioblastoma and / or assessment of the response of an individual to therapy for glioblastoma treatment. In particular, expression analysis of two or more specific genes provided in the invention is determined to predict outcome for the individual and / or to predict if the individual will respond to therapy, such as chemoradiation, for example. In specific embodiments, a multigene set from a sample from the individual is compared to a reference set of housekeeping genes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
InactiveUS20090215683A1Poor prognosisSuppress expressionCompound screeningOrganic active ingredientsNon-small cell lung cancer (NSCLC)Co activation
Owner:ONCOTHERAPY SCI INC
Cancer markers
InactiveUS7901876B2Prognosis is dramatically affected by Numb statusImproved prognosisPeptide/protein ingredientsMicrobiological testing/measurementGene productGene
Owner:IFOM FOND INST FIRC DI ONCOLOGIA MOLECOLARE
ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS
InactiveUS20100273660A1High resolutionPoor prognosisCompound screeningApoptosis detectionOncogenomicsWilms' tumor
In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.The present invention also provides methods for identifying and validating tumor suppressor genes by screening pools of shRNAs that target genomic regions deleted in human cancers, such as human hepatocellular carcinomas. The present invention also provides validated tumor suppressor genes, and methods of inhibiting cell proliferation and / or tumor growth, for example by expression of such tumor suppressor genes.
Owner:COLD SPRING HARBOR LAB INC
Bone repairing material using a chondrocyte having the potential for hypertrophy and a scaffold
InactiveUS20060212125A1Poor prognosisPromote osteogenesisBone implantInorganic non-active ingredientsBiological bodyBiophysics
The present invention provides a composite material for enhancing or inducing osteogenesis in a biological organism, comprising A) a chondrocyte having the potential for hypertrophy, and B) a scaffold that is biocompatible with the biological organism. The present invention also provides a method for producing a composite material for enhancing or inducing osteogenesis in a biological organism, comprising A) providing a collected chondrocyte having the potential for hypertrophy, and B) culturing the chondrocyte having the potential for hypertrophy on a scaffold that is biocompatible with the biological organism.
Owner:ASAHI KOGAKU KOGYO KK
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
InactiveUS20190106494A1High expressionIncrease aggressivenessHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseMonoclonal antibody
The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
Owner:ASKGENE PHARM INC +1
Method and apparatus for delivery into the fetal trachea
InactiveUS20120184808A1Prevent leakagePoor prognosisBronchoscopesLaryngoscopesTracheal obstructionObstetrics
An method and apparatus for using polymerizable hydrogels to cause tracheal obstruction (TO) for treatment of pulmonary hypoplasia disorders to improve lung development in-utero. Use of the compound can cause effective TO for the purposes of inducing lung growth.
Owner:SAINT LOUIS UNIVERSITY
Copy number alterations that predict metastatic capability of human breast cancer
InactiveUS20090155805A1Poor prognosisMicrobiological testing/measurementBreast cancer metastasisChromosome regions
Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided.
Owner:VERIDEX LCC
Immune modulators in combination with radiation treatment
InactiveUS20170360932A1Good curative effectPoor prognosisPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsImmune modulatorNormal tissue
Methods for treating tumors by administering ionizing radiation and an immune modulator to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining immune modulators with ionizing radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with an immune modulator based on patient-specific biomarker signatures.
Owner:VARIAN MEDICAL SYSTEMS
Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
InactiveUS20090041773A1Elevate level of expressionPoor prognosisMicrobiological testing/measurementBiological material analysisSignal onProliferative disease
Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
Owner:XOMA TECH LTD
Composition for treatment and diagnosis of pancreatic cancer
InactiveUS20140010756A1Inhibit growthInhibiting metastasisIn-vivo radioactive preparationsPeptide/protein ingredientsCytotoxicityOncology
This invention relates to a pharmaceutical composition for inhibiting the growth and / or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor β (FRβ) protein of an FRβ (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FRβ (+) macrophage is distributed around pancreatic cancer cells at the invasive front.
Owner:KAGOSHIMA UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com